- Home
- WOLF vs LRMR Comparison
WOLF vs LRMR Comparison
Compare WOLF & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WOLF
- LRMR
- Stock Information
- Founded
- WOLF 1987
- LRMR N/A
- Country
- WOLF United States
- LRMR United States
- Employees
- WOLF N/A
- LRMR N/A
- Industry
- WOLF Semiconductors
- LRMR Biotechnology: Pharmaceutical Preparations
- Sector
- WOLF Technology
- LRMR Health Care
- Exchange
- WOLF Nasdaq
- LRMR Nasdaq
- Market Cap
- WOLF 200.8M
- LRMR 204.9M
- IPO Year
- WOLF 1993
- LRMR N/A
- Fundamental
- Price
- WOLF $1.42
- LRMR $3.78
- Analyst Decision
- WOLF Hold
- LRMR Strong Buy
- Analyst Count
- WOLF 13
- LRMR 7
- Target Price
- WOLF $10.21
- LRMR $17.86
- AVG Volume (30 Days)
- WOLF 26.1M
- LRMR 1.6M
- Earning Date
- WOLF 08-20-2025
- LRMR 08-19-2025
- Dividend Yield
- WOLF N/A
- LRMR N/A
- EPS Growth
- WOLF N/A
- LRMR N/A
- EPS
- WOLF N/A
- LRMR N/A
- Revenue
- WOLF $761,300,000.00
- LRMR N/A
- Revenue This Year
- WOLF N/A
- LRMR N/A
- Revenue Next Year
- WOLF $14.42
- LRMR N/A
- P/E Ratio
- WOLF N/A
- LRMR N/A
- Revenue Growth
- WOLF N/A
- LRMR N/A
- 52 Week Low
- WOLF $0.39
- LRMR $1.61
- 52 Week High
- WOLF $3.33
- LRMR $9.50
- Technical
- Relative Strength Index (RSI)
- WOLF 47.15
- LRMR 59.91
- Support Level
- WOLF $1.38
- LRMR $3.42
- Resistance Level
- WOLF $1.60
- LRMR $3.97
- Average True Range (ATR)
- WOLF 0.18
- LRMR 0.35
- MACD
- WOLF -0.01
- LRMR -0.01
- Stochastic Oscillator
- WOLF 5.97
- LRMR 57.62
About WOLF Wolfspeed Inc.
Wolfspeed Inc is involved in the manufacturing of wide bandgap semiconductors. It is focused on silicon carbide and gallium nitride materials and devices for power and radio-frequency (RF) applications. The company serves applications such as transportation, power supplies, inverters, and wireless systems. Geographically, it derives a majority of its revenue from Europe and the rest from the United States, China, Hong Kong, Asia Pacific, and other regions.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.